Compare Materials Select Sector SPDR Fund (XLB) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Materials Select Sector SPDR Fund vs Zimmer Biomet Holdings Inc — how do they compare? Materials Select Sector SPDR Fund trades at $49.43 (market cap $7.73B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.2× Materials Select Sector SPDR Fund's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Materials Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Materials Select Sector SPDR Fund for 70 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| XLB | ZBH | |
|---|---|---|
Market Cap | $7.73B | $16.95B |
Volume | 13,681,146 | 2,505,240 |
52-Week High | $53.67 | $103.98 |
52-Week Low | $42.23 | $79.58 |
Typical Hold Time | 70 Days | 89 Days |
Sector | — | Health |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
XLB, the Materials Select Sector SPDR ETF, trades at $49.27, up 0.59% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF's portfolio is heavily concentrated in chemicals (49% of assets), and recent analysis suggests limited upside after a sector rebound, with construction materials moderately overvalued and chemicals showing weak value-quality scores.
Outlook remains cautious due to cyclical pressures and high concentration risk, though long-term infrastructure and manufacturing trends offer support. Investors face headwinds from sector volatility and priced-in recovery, but the ETF provides low-cost exposure to large-cap U.S. materials stocks for those seeking broad sector allocation.
Zimmer Biomet (ZBH) trades at $88.91, up 0.47% on the day, with a bearish technical signal but strong recent earnings beats. The company reported Q2 2026 EPS of $2.07, exceeding expectations, and maintains a solid gross profit margin of 69.87%. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated. Analyst consensus is a 'Buy' with a $103.11 price target, indicating potential upside from current levels.
The outlook for ZBH is cautiously optimistic, supported by earnings momentum and a diversified medical technology portfolio. Key risks include rising debt levels, with debt-to-asset ratio increasing to 32.57% in 2025, and competitive pressures in the healthcare sector. Institutional ownership trends show continued interest, but investors should monitor margin sustainability and capital expenditure efficiency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
